These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 23286563)

  • 1. Marked improvement of elderly postprandial hypotension by dipeptidyl peptidase IV inhibitor.
    Yonenaga A; Ota H; Honda M; Koshiyama D; Yagi T; Hanaoka Y; Yamamoto H; Yamaguchi Y; Iijima K; Akishita M; Ouchi Y
    Geriatr Gerontol Int; 2013 Jan; 13(1):227-9. PubMed ID: 23286563
    [No Abstract]   [Full Text] [Related]  

  • 2. [Vildagliptin].
    Iwamoto Y
    Nihon Rinsho; 2011 May; 69(5):865-70. PubMed ID: 21595273
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with type 2 diabetes.
    Matikainen N; Taskinen MR
    Diabet Med; 2013 Jun; 30(6):756-7. PubMed ID: 23215876
    [No Abstract]   [Full Text] [Related]  

  • 4. Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.
    Scherbaum WA
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():1-2. PubMed ID: 19385977
    [No Abstract]   [Full Text] [Related]  

  • 5. A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors.
    Aouidad I; Fite C; Marinho E; Deschamps L; Crickx B; Descamps V
    JAMA Dermatol; 2013 Feb; 149(2):243-5. PubMed ID: 23426497
    [No Abstract]   [Full Text] [Related]  

  • 6. Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats.
    Maeda S; Matsui T; Yamagishi S
    Int J Cardiol; 2012 Jun; 158(1):171-3. PubMed ID: 22564388
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
    Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
    Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vildagliptin in clinical practice: a review of literature.
    Banerjee M; Younis N; Soran H
    Expert Opin Pharmacother; 2009 Nov; 10(16):2745-57. PubMed ID: 19874253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Between reduction of glucose fluctuations and increased therapeutic adherence: an example of the benefits of vildagliptin in an elderly diabetic patient.
    Chilelli NC; Burlina S; Sartore G; Lapolla A
    Aging Clin Exp Res; 2015 Feb; 27(1):85-7. PubMed ID: 24781833
    [No Abstract]   [Full Text] [Related]  

  • 10. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
    Del Prato S
    Int J Clin Pract Suppl; 2007 Aug; (154):38-48. PubMed ID: 17593276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Islet cell function is as interesting as insulin resistance for T2DM treatment options.
    Göke B
    Int J Clin Pract Suppl; 2008 Mar; (159):1. PubMed ID: 18269434
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients.
    Bunck MC; Poelma M; Eekhoff EM; Schweizer A; Heine RJ; Nijpels G; Foley JE; Diamant M
    J Diabetes; 2012 Jun; 4(2):181-5. PubMed ID: 22051153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
    Gallwitz B
    Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
    [No Abstract]   [Full Text] [Related]  

  • 15. Incretin therapy and beta cell function.
    Goundan PN; Underwood P; Mantzoros CS
    Metabolism; 2015 Feb; 64(2):157-9. PubMed ID: 25456457
    [No Abstract]   [Full Text] [Related]  

  • 16. New treatments for type 2 diabetes--the DPP4 inhibitors.
    Gadsby R
    Prim Care Diabetes; 2007 Dec; 1(4):209-11. PubMed ID: 18632049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes.
    Prescrire Int; 2008 Oct; 17(97):188. PubMed ID: 19534040
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly.
    Halimi S; Raccah D; Schweizer A; Dejager S
    Curr Med Res Opin; 2010 Jul; 26(7):1647-56. PubMed ID: 20441397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
    Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
    Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic use and adverse events of incretin-related drugs].
    Ishikawa M; Yamada Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():699-702. PubMed ID: 22768601
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.